Expert opinion of an Italian working group on the assessment of cognitive, psychological, and neurological outcomes in pediatric, adolescent, and adult patients with phenylketonuria.
Filippo MantiStefania CavigliaChiara CazzorlaAnnamaria DicintioAndrea PilottoAlessandro P BurlinaPublished in: Orphanet journal of rare diseases (2022)
Phenylketonuria (PKU) is an inherited metabolic disease characterized by a defective conversion of phenylalanine (Phe) to tyrosine, potentially leading to Phe accumulation in the brain. Dietary restriction since birth has led to normal cognitive development. However, PKU patients can still develop cognitive or behavioral abnormalities and subtle neurological deficits. Despite the increasing evidence in the field, the assessment of neurocognitive, psychopathological, and neurological follow-up of PKU patients at different ages is still debated. The high interindividual variability in the cognitive outcome of PKU patients makes the specificity of the neurocognitive and behavioral assessment extremely challenging. In the present paper, a multidisciplinary panel of Italian PKU experts discussed different tools available for cognitive, psychopathological, and neurological assessment at different ages based on the existing literature and daily clinical practice. This study aims to provide evidence and a real-life-based framework for a specific clinical assessment of pediatric, adolescent, and adult patients affected by PKU.
Keyphrases
- end stage renal disease
- clinical practice
- newly diagnosed
- ejection fraction
- chronic kidney disease
- systematic review
- peritoneal dialysis
- mental health
- prognostic factors
- traumatic brain injury
- multiple sclerosis
- metabolic syndrome
- physical activity
- patient reported outcomes
- brain injury
- glycemic control
- childhood cancer